目的:这项研究的目的是描述丹麦喉乳头状瘤病(LP)的发病率和人口统计学,包括性别和年龄分布,复发率,和HPV亚型,使用一种新的寄存器识别方法。
方法:使用SNOMED代码从丹麦病理学数据库中提取数据,而不是使用丹麦国家卫生注册中心的ICD代码的常规方法。衍生的病理记录由三名医生手动验证。研究期为1994-2021年。根据年龄将患者分类为青少年发病RRP(JoRRP)(如果<18岁)或成人发病RRP(AoRRP)(如果18岁或以上)。
结果:我们确定了1819例RRP患者(JoRRP:56;AoRRP:1763)。JoRRP每100,000居民的总发病率为0.17,AoRRP为1.45。绝大多数(72%)的患者是男性,但RRP发病年龄或性别间复发率无显著差异.3岁以下儿童的复发概率最高。使用SNOMED代码提取数据导致关于活检总数的阳性预测值为99%,关于个体的阳性预测值为98%。在整个研究期间发病率下降。
结论:丹麦和挪威的RRP发病率和复发率相当。在这项研究中,发现丹麦病理学注册是一种非常有价值的鉴定LP患者的方法.可以使用这种方法评估全国HPV疫苗接种计划的效果,因为接种疫苗的队列开始变老和繁殖。
方法:基于回顾性注册的国家队列研究,证据水平3喉镜,2024.
OBJECTIVE: The aim of this study is to describe the incidence and demographics of laryngeal
papillomatosis (LP) in Denmark, including sex and age distribution, recurrence rates, and HPV subtypes, using a new method of register identification.
METHODS: The data were extracted from the Danish Pathology Data Bank using SNOMED codes instead of the usual method using ICD codes from the Danish National Health Register. The derived pathology records were manually verified by three medical doctors. The study period was 1994-2021. Patients were categorized according to age as either juvenile-onset RRP (JoRRP) if <18 years or adult-onset RRP (AoRRP) if 18 years or older.
RESULTS: We identified 1819 RRP patients (JoRRP: 56; AoRRP:1763). The overall incidence per 100,000 inhabitants were 0.17 for JoRRP and 1.45 for AoRRP. The vast majority (72%) of the patients were male, but there was no significant difference in age at onset of RRP or recurrence rates between the sexes. Children below 3 years of age had the highest recurrence probability. Extracting data using SNOMED codes resulted in a positive predictive value of 99% regarding total number of biopsies and 98% regarding individuals. The incidence decreased throughout the study period.
CONCLUSIONS: Comparable incidence and recurrence rates of RRP were found between Denmark and Norway. In this study, the Danish Pathology Register was found to be a highly valuable method for identifying LP patients. The effect of the nationwide HPV vaccination program can be evaluated using this method as the vaccinated cohort is starting to grow older and reproduce.
METHODS: Retrospective registry-based national cohort study, level of evidence 3 Laryngoscope, 2024.